ViroPharma 8-K 2007
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): May 2, 2007
(Exact Name of Registrant as Specified in its Charter)
(Registrants Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 2.02 Results of Financial Operations and Financial Condition.
On May 2, 2007, ViroPharma Incorporated (the Company) issued a press release announcing its financial results for its first quarter ended March 31, 2007. A copy of the press release is set forth as Exhibit 99.1 attached hereto.
Item 7.01 Regulation FD Disclosure.
On May 1, 2007, the Company announced the decision to establish a wholly owned European subsidiary to execute on the European regulatory strategy and commercialization of maribavir, the Companys oral antiviral drug candidate targeting cytomegalovirus, without a strategic partner. A copy of the press release is set forth as Exhibit 99.2 attached hereto.
Additionally, the Company announced that Robert Pietrusko, Pharm. D. has joined the company as vice president of global regulatory affairs and quality and as a member of the management team.
Item 9.01 Financial Statements and Exhibits.
The following exhibits are attached to this Form 8-K:
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Index of Exhibits